Oncolytics Biotech Inc.
www.oncolyticsbiotech.comOncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.
Read more
Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.
Read more
Country
City (Headquarters)
Calgary
Industry
Employees
11-50
Founded
1998
Estimated Revenue
$1,000,000 to $5,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Vice President , Product Development
Email ****** @****.comPhone (***) ****-****Senior Vice President Global Licensing and Business Development
Email ****** @****.comPhone (***) ****-****Executive Director Translational Science
Email ****** @****.comPhone (***) ****-****Chief Financial Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(46)
